semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Chronic Kidney Disease Bloodpressure Hypertension Adults ≥16 years of age who meet the eGFR which will be determined based on whether participants have 1. at least two eGFR in the last three months that are <30 mL/min/1.73m2 or 2. prior diagnosis of CKD (per electronic chart review) and at least one eGFR <30 mL/min/1.73m2 3. history of hypertension 4. mid-arm circumference between 22-37cm (BP cuff size limitation) and be able to provide consent to participate in our study  Those who are or are planning to become pregnant, due to inability to take multiple classes of anti-hypertensive agents are marginally housed, due to concerns regarding routine follow-up are actively participating in a different interventional trial that may affect blood pressure are unwilling to consent to participate institutionalized individuals or prisoners are actively abusing illicit drugs or alcohol have a history of poor or doubtful compliance (e.g., frequently missed appointments) have office SBP >170 mmHg are already taking ≥5 anti-hypertensive medications (any classes, including diuretics) have cognitive impairment prohibiting participation in the study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parathyroid Gland Adenoma Primary Hyperparathyroidism Positive 4 dimensional computed tomography (4D CT) for single gland (adenoma) primary hyperparathyroidism Preoperative serum calcium levels >= 10.9 mg/dL Preoperative parathyroid hormone (PTH) elevated beyond normal range or inappropriately high for associated calcium level Patient has no history of prior neck surgery or external radiation to neck for malignant conditions Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 Subject or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure  Patient has recurrent hyperparathyroidism CT positive for multiple gland disease Patient has inability to tolerate 4D CT scan (for example; contrast intravenous (IV) allergy, claustrophobia, renal disease) Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Pregnant or nursing female subjects; may be determined in the preoperative evaluation Unwilling or unable to follow protocol requirements Any condition which in the investigator's opinion deems the subject an unsuitable candidate to undergo observational study (may also preoperative testing results including electrocardiography [EKG], chest x-ray, or pulmonary function tests that preclude a wide excision in the operating room)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Hyperparathyroidism elevated parathormone serum levels normal or elevated calcium serum levels  age younger than 18 years renal and liver failure and insufficiency active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc) any type of cancer malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption transplantation sarcoidosis endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism familial hypocalciuric hypercalcemia hypophosphoremia sustained by genetic causes or secondary to other causes
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 6.0-25.0,  Cerebral Palsy diagnosis of diplegic CP (Rosenbaum et al., 2007) GMFCS levels I, II, and III aged between 6 and 25 years bilateral surgery  other diagnosis than cerebral palsy severe mental retardation (IQ < 50)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Osteo Arthritis Knee Subject is between 18 and 75 years of age 2. Subject is indicated for a unilateral total knee arthroplasty (TKA) based on the approved labeling of the device 3. Subject has no history of previous prosthetic replacement device or orthopedic surgeries on the operative knee 4. Subject is willing and able to provide informed consent to participate in the study; 5. Subject is willing and able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits  Subjects will be excluded if, in the opinion of the Investigator, the subject does not qualify based on approved labeling requirements or Subject criteria
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thyroid Thyroidectomy Myocardial Function Patient is over 18 years old Patient scheduled for a non-emergency operation Patient signs and dates a written informed consent form (ICF) and indicates an understanding of the study procedures No previous cardiologic history Normal PTH values (no transient hypoparathyroidism)  Patient is underage ( under 18 years old) Patient had a previous operation at the thyroid or parathyroids Patient inability to participate in follow-up appointments Patient is participating in another clinical trial which may affect this study's outcomes Patient with TSH values outside the range of normal values Pathologic Ca2+ , Vit D, P, PTH, pre and post-operative values Diabetes Mellitus, Hypertension, History of any heart, lung or systemic disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 50.0-70.0,  Healthy, Postmenopausal Women Postmenopausal female: 50-70 years Women: lack of menses for at least one year and FSH 23-116.3 mlU/mL Subject is willing and able to comply with the study protocols Subject is willing to participate in all study procedures BMI 25.0 kg/m2 Weight ≥ 110 pounds  BMI ≥ 40 kg/m2 Dislike or allergy for grape products and raisins Self-reported use of daily anticoagulation agents including aspirin, NSAIDs Vegan, Vegetarians, food faddists or those consuming a non-traditional diet Alcohol consumption > 3 drinks/week (i.e. 1 bottle of beer, 1 glass of wine, and 1 shot of hard liquor) Fruit consumption ≥ 2 cups/day Vegetable consumption ≥ 3 cups/day for females Fatty Fish ≥ 3 times/week Coffee/tea ≥ 3 cups/day Dark chocolate ≥ 3 oz/day
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Vitamin D Deficiency Polytrauma Orthopedic Disorder Males and females age 18-65 years 2. One or more orthopaedic injuries on admission 3. Admission injury severity score (ISS)≥16 4. Anticipated stay in hospital of more than 7 days  Pregnancy (if patient becomes pregnant during the study, she will be removed from the study) 2. End stage kidney disease 3. Patients on furosemide, thiazide, or corticosteroid therapy 4. Patients with chronic liver disease 5. Patients with recent history of vitamin D supplementation more than 5000 IU/day 6. Patients actively undergoing chemo or immunotherapy 7. Patients with hematologic and solid malignancies 8. Patients receiving treatment for osteoporosis 9. Patients with "nothing per mouth" status secondary to any preceding procedures involving their GI system (e.g. patients with colectomy performed on this admission secondary to gunshot wound to abdomen)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Osteogenesis Imperfecta Brittle Bone Disorders Female with OI who has delivered an infant of at least 24 weeks' gestation Participant in the BBD Contact Registry  Inability to provide informed consent and complete survey Males Women with OI who have not delivered children and gestations associated with higher order multiples
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 1.5-999.0,  Non Invasive Prenatal Diagnosis older than 18 years old pregnant woman between 9 and 34 weeks of gestation Couple at risk (based on family history or echographic findings) for one of the following diseases: Huntington's disease, Steinert's myotonic dystrophy, fragile X and spinocerebellar ataxias 1, 2 or 3 Written informed consent was obtained for the study Prenatal diagnosis has been programmed for the current pregnancy during which maternal blood is collected Couple molecular diagnosis results for one of the following diseases (Huntington's disease, Steinert's myotonic dystrophy, fragile X and spinocerebellar ataxias 1, 2 or 3 ) MUST BE  Couple Genomic DNA are unavailable Subjects at risk of transmitting the family disease, but not wishing to know their molecular status individuals under guardianship by court order
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hyperparathyroidism, Primary Parathyroidectomy Patient is over 18 years old 2. Patient scheduled for a non-emergency operation 3. Patients diagnosed with PHPT: i) one or more samples of total serum calcium above the upper limit of normal value for the laboratory (hypercalcemia) ii) serum albumin within the normal range iii) hypercalcemia with normal or elevated PTH levels iv) serum 25(OH) vitamin D more than 20 ng/ml (50nmol/lt) 4. Patient eligible for parathyroid surgery: PHPT with one or more of the following i) age less than 50 years ii) serum calcium level more than 1mg/dl above the upper limit of normal iii) T score of less than -2.5 at any site, or non traumatic osteoporotic fracture by history or VFA (Vertebral Fracture Assessment) iv) history of renal colic or evidence of lithiasis/calcinosis by x-Ray or ultrasound v) creatinine clearance of less than 60ml/min vi) hypercalciuria (more than 400mg/ day) 5. Patient signs and dates a written informed consent form (ICF) and indicates an understanding of the study procedures  Patient is participating in another clinical trial which may affect this study's outcomes 2. Patient with recurrent hyperparathyroidism 3. Previous operation at the thyroid and parathyroid glands or neck irradiation 4. Noneuthyroid condition 5. Primary hyperparathyroidism due to hyperplasia or multiple adenomas 6. Secondary hyperparathyroidism 7. Primary or secondary hypoparathyroidism 8. Diabetes mellitus 9. Chronic renal failure 10. Systemic diseases (e.g. infections, neoplasms) 11. Hypoalbuminemia 12. Use of drugs that influences calcium metabolism (Vitamin D analogues, oral calcium supplements, bisphosphonates, teriparatide, thiazide diuretics, aromatase inhibitors) 13. Known neuromuscular disorders due to other causes 14. Factors affecting acoustic reflex: i) Conductive or sensorineural hearing loss (hearing threshold better than 80dBs (decibells) in every testing frequency) ii) Otosclerosis iii) Middle ear dysfunction (acute or chronic inflammation) iv) Facial nerve dysfunction v) Retrocochlear damage (acoustic neurinoma, vestibular Schwannoma) vi) Impaired stapedius muscle
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-75.0,  Chronic Kidney Disease Mineral and Bone Disorder Men and women ages 30-75 years old, any race Moderate CKD, based on the last set of labs done in the past year, defined as: Glomerular Filtration Rate (GFR) category G3a (eGFR 45-59 mL/min) with A2 or A3 albuminuria or proteinuria by positive dipstick or urine protein/creatinine ratio (UPCR); -or G3b (eGFR 30-44 mL/min), with or without evidence of albuminuria (any A1-A3) or proteinuria. (Figure 1) -or Healthy control with no diagnosis or evidence of CKD Female subjects must be post-menopausal, surgically sterile, or confirmed not pregnant by pregnancy test and not breastfeeding. Subjects must be on stable doses of medications (except those noted in  ) for at least 6 weeks prior to the study Plans to initiate dialysis within 6 months Labs based on the last set done in the past year: Hypercalcemia defined as serum calcium > 10.5 mg/dL Hyperkalemic > 5.5 mg/dL Prescribed a phosphate binder medication Small bowel resection, bariatric surgery. Medically unstable or poorly controlled hypertension, diabetes, or gastrointestinal disorders in the opinion of the physicians on the study team Calcitriol, ergocalciferol, cholecalciferol, vitamin D analogs, calcimimetics, PTH analogues, calcium supplements, multivitamins/mineral and other medications that may alter phosphorus metabolism must be off for at least 6 weeks prior to study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Hepatitis B HBeAg negative Chronic HBV infection who are having HBV DNA-undetectable. ALT <40 IU/ml No Advanced fibrosis[LSM <14 KPa] TDF/ETV >1 year Clinical Relapse after stopping NA will be defined as HBV DNA>2000IU/ml and ALT > 80IU  HBeAg+ CHB Pregnancy Cirrhosis on biopsy or LSM >14 Co-infection HIV/HCV/HDV Immunosuppressive therapy Renal failure S.Bilirubin>2mg/dl Patient having neutropenia
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Myelodysplastic Syndromes Patients must have a confirmed diagnosis of myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) proven by bone marrow biopsy/aspirate. 2. Patients with cytopenias (blood cell counts lower than the institutional lower limit of normal within the eight weeks prior to the study) who are receiving or received red blood cell transfusions observation platelet transfusions erythropoietin granulocyte colony-stimulating factors granulocyte-macrophage colony-stimulating factors hydrea 3. Age >18 years. 4. Predicted life expectancy of at least 12 weeks. 5. Patients should be expected to stay on the same therapy for the period of the study. 6. Patients who do not have an indication for and/or are unable to tolerate a hypomethylating agent are eligible for the study. 7. Reproductive requirements: Female patients must meet one of the following Postmenopausal for at least one year before the screening visit, or Surgically sterile, or  A potential subject who meets any of the following is ineligible to participate in the study. 1. Previously received hypomethylating agents. 2. Allergy to black raspberries. 3. Inability to swallow oral medication. 4. Inability or unwillingness to comply with the BRB administration requirements. 5. Uncontrolled intercurrent illness, including, but not limited to, symptomatic congestive heart failure, or psychiatric illness/social situations, that, in the treating investigator's discretion, would limit compliance with study requirements. 6. Active infection not well controlled by antibacterial or antiviral therapy. 7. Pregnant or lactating women. 8. Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Pain Enrolled patients will be males or females aged over 18 years have pain for at least 3 months due to mild to moderate osteoarthritis of the knee (meeting American College of Rheumatology clinical and radiographic criteria), of at least moderate intensity (pain intensity score over the last 24 hours before enrolment ≥ 4/10) with a BMI above 30 kg/m² and no other pain conditions accounting for their disability The skin will be intact and no blessed All female patients should take contraception during all study and at least 30 days after closer All patients must sign informed consent All patients will be recruited from the Department of Nutrition, Ambroise Paré University Hospital and treatment will be given during a dedicated day care clinic  Patients necessitating surgery with relative contraindications to capsaicin patches, particularly with unstable hypertension or cardiac condition past history of capsaicin use will not be included
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Total Knee Arthroplasty Patients undergoing first time revision knee replacement for aseptic loosening or wear of the components Patient has signed an ethics committee approved consent form rTKR to be performed at The Royal Devon and Exeter Hospital AORI class 2 defects of femur and/or tibia Skeletally mature male or female Patient is willing and able to comply with postoperative scheduled clinical and radiological evaluations and rehabilitation Patient must be suitable for a rTKR with the Triathlon TS system i.e. must not have gross collateral ligament laxity  Refusal to consent to participate in the study Patients known to have an infected joint replacement prior to revision surgery Patients identified with an unexpected infected joint replacement identified per-operatively AORI class 1 defects of tibia or femur where metaphyseal cone fixation is not indicated AORI class 3 defects of tibia and femur where distal femoral replacement or proximal tibial replacement is required Cases of ligamentous instability where condylar knee revision is not indicated Patient is diagnosed with a systemic disease or metabolic disorder leading to progressive bone deterioration Patient has a neuromuscular or neurosensory deficiency Patients undergoing patella revision in isolation Pregnancy